The EZTEAM study found ceftazidime-avibactam effective against antibiotic-resistant bacteria and it is mainly used as a second line of treatment for these infections. hubs.ly/Q03x_jTL0 #PlainLanguageSummary

New study highlights interim ECHELON-3 study results comparing novel combination approaches for relapsed/refractory DLBCL. Discover how an antibody-drug conjugate plus immunomodulatory therapy performs against standard treatment: hubs.ly/Q03x_l3N0 #PLSP #Hematology

Swedish registry data highlights important distinctions in warm autoimmune hemolytic anemia presentations. See how this rare condition differs when occurring as a primary disorder versus developing secondary to other health challenges: hubs.ly/Q03x_y9s0 #PLSP #Hematology

Clinical trial results reveal important findings for pulmonary arterial hypertension management using combination therapy. See how adding an oral prostanoid to background treatments affects clinical worsening events in this challenging rare disease hubs.ly/Q03x_DRv0 #PLSP

The REAL-HLH study reveals real-world outcomes using an interferon-gamma inhibitor in U.S. patients with hemophagocytic lymphohistiocytosis. Learn how this targeted therapy addresses the dangerous immune overactivation in rheumatologic HLH cases: hubs.ly/Q03BJJRJ0 #PLSP

Latest research highlights patient satisfaction data from the ALLEGRO study examining a targeted JAK/TEC inhibitor for immune-mediated hair loss. See how participants rated their hair regrowth experience after 6 and 12 months of treatment: hubs.ly/Q03BJJVB0 #PLSP

New study examines a novel treatment approach for HoFH patients who respond poorly to standard cholesterol therapies. hubs.ly/Q03BJP6D0 #KnowFH Family Heart Foundation Chief Medical Officer Family Heart Foundation #RunsintheFamily National Lipid Association ASPC American College of Cardiology American Academy of Pediatrics Association of Black Cardiologists

Research shows asthma and COPD patients often turn to social media or healthcare providers to understand their condition better. Study emphasizes need for clearer guidance on when to expect symptom improvements hubs.ly/Q03BJQdJ0 #PLSP #RespiratoryMedicine #AsthmaAwareness

Research explores innovative preventive approach for migraine sufferers using every-other-day oral therapy targeting CGRP receptors. It evaluates impact on reducing monthly migraine frequency. hubs.ly/Q03BJP_m0 #PLSP #MigraineRelief #NeurologyResearch

New study evaluates an oral CGRP receptor antagonist as preventive migraine therapy. Research shows promising results with every-other-day dosing schedule for reducing monthly migraine days. hubs.ly/Q03BJPJK0 #PLSP #MigraineRelief #NeurologyResearch

New research explores an antifungal therapy for serious fungal infections in immunocompromised children aged 1-18. Study aims to establish pediatric-specific data on effectiveness and optimal dosing beyond current adult-based protocols hubs.ly/Q03BJRrD0 #PLSP

Research targets better treatment protocols for immunocompromised children with serious fungal infections. Study evaluates safety and effectiveness of an FDA/EMA-approved antifungal in pediatric patients aged 1-18 years hubs.ly/Q03BJRn50 #PLSP #PediatricResearch

New phase 3 trial data reveals potential breakthrough for advanced GIST patients. Research evaluates an innovative fourth-line treatment approach for those who've progressed on standard tyrosine kinase inhibitor therapies hubs.ly/Q03BJWlx0 #PLSP #PrecisionOnco #RareCancers

New research from the DELIVER study evaluates an IV monoclonal antibody therapy for migraine prevention. 1.5-year study focused on patients who hadn't responded to multiple previous treatments hubs.ly/Q03BJWM40 #PLSP #MigraineRelief #NeurologyResearch

New research from the DELIVER study evaluates an IV monoclonal antibody therapy for migraine prevention. 1.5-year study focused on patients who hadn't responded to multiple previous treatments hubs.ly/Q03BJZpY0 #PLSP #MigraineRelief #NeurologyResearch

Research explores progressive pulmonary fibrosis care across five European countries. Study documents patient experiences and treatment approaches, providing valuable guidance for improving PPF management hubs.ly/Q03BKtbW0 #PLSP #PulmonaryFibrosis #RareDiseaseCare

Research examines how gene therapy is transforming Hemophilia A treatment. Unlike traditional Factor VIII concentrates or emicizumab, ROCTAVIAN enables patients' bodies to produce their own clotting protein hubs.ly/Q03BKzVt0 #PLSP #HemophiliaA #GeneTherapy

New study examines a novel IFNγ-blocking agent for hemophagocytic lymphohistiocytosis (HLH). Discover how this targeted approach performed in the REAL-HLH study for patients with rheumatologic disease-associated forms of this rare condition hubs.ly/Q03BJM170 #PLSP

The ALLEGRO trial documents patient-reported outcomes with a novel oral JAK inhibitor for alopecia areata. Learn how this targeted therapy affected satisfaction with hair regrowth compared to placebo in this immune-mediated hair loss condition hubs.ly/Q03BJN-20 #PLSP

New study highlights long-term outcomes with an ANGPTL3 inhibitor for homozygous familial hypercholesterolemia. hubs.ly/Q03BJNsR0 #KnowFH Family Heart Foundation Chief Medical Officer @familyHeartFdn #RunsintheFamily National Lipid Association ASPC @ACCintouch American Academy of Pediatrics Association of Black Cardiologists